Search clinical trials for: first line treatment failure

Total 92002 results

XIANG YANQUN

Not yet recruiting

Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy

Nasopharyngeal Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

HCC

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

China
Hunan Cancer Hospital

Not yet recruiting

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Melanoma
Dr. Inge Winter
Universität Münster

Recruiting

The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. (INTENSIFY BD)

Bipolar Depression

Austria, Germany, Italy, Spain, United Kingdom
Dr. Inge Winter
Universität Münster

Recruiting

The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. (INTENSIFY MDD)

Major Depressive Disorder | Treatment Resistant Depression

Austria, Germany, Italy, Spain, United Kingdom
Dr. Inge Winter
Universität Münster

Recruiting

The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. (INTENSIFY SZ)

Schizophrenia and Related Disorders | Early Treatment-Resistance

Austria, Germany, Italy, Spain, United Kingdom
Fudan University

Not yet recruiting

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

TNBC - Triple-Negative Breast Cancer
Pulnovo Medical (Wuxi) Co., Ltd.
The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaborators

Recruiting

A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure (PADN-HF-PH)

Cardiovascular Diseases | Vascular Diseases | Heart Failure | Hypertension | Pulmonary Hypertension | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection Fraction

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Avatrombopag Combined With IST as First-line Treatment for SAA

Severe Aplastic Anemia

China
Dr. Inge Winter
Universität Münster

Not yet recruiting

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (INTENSIFY)

Bipolar Depression | Major Depressive Disorder | Schizophrenia and Related Disorders

Israel
Bristol-Myers Squibb

Recruiting

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM) (DISCOVER-HCM)

Obstructive Hypertrophic Cardiomyopathy

United States, Puerto Rico
Nanjing First Hospital, Nanjing Medical University

Recruiting

Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome (ODT-CRS)

Heart Failure | Kidney Diseases | Heart Valve Diseases | Coronary Heart Disease | Kidney Injury | Dialysis; Complications

China
Nanjing First Hospital, Nanjing Medical University

Recruiting

Cohort Study of Heart Failure With Preserved Ejection Fraction in Chinese Han

Heart Failure

China
Sun Yat-sen University

Recruiting

PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure

PD-1 Inhibitor | G-CSF

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor (RALOXBTC)

Cholangioadenoma

China
Fudan University

Not yet recruiting

Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study

Metastatic Colorectal Cancer
Centre Leon Berard

Recruiting

Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas (REGOSTA)

Osteosarcoma | Ewing Sarcoma | Chondrosarcoma | Leiomyosarcoma | Angiosarcoma | Bone Sarcoma | Undifferentiated Pleomorphic Sarcoma

France
Xin-Hua Xu

Recruiting

A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.

Nonsquamous Non-Small Cell Lung Cancer

China
Xin-Hua Xu

Recruiting

A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

Nonsquamous Non-Small Cell Lung Cancer

China
Chongqing Medical University

Completed

Strategy, Efficacy and Safety of Medication Usage in Heart Failure Patients Who Were Intolerable to GDMT (SEMI)

Heart Failure With Reduced Ejection Fraction

China
Institute of Tropical Medicine, Belgium
Damien Foundation

Active, not recruiting

Novel Triple-dose Tuberculosis Retreatment Regimen (Tri-Do-Re)

Tuberculosis | Pulmonary Tuberculosis | Multidrug-resistant Tuberculosis | Resistance to Tuberculostatic Drugs

Niger
Institute of Hematology & Blood Diseases Hospital...

Terminated

Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment (BID-PERAL)

Acquired Pure Red Cell Aplasia

China
Sun Yat-sen University

Active, not recruiting

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Nasopharyngeal Carcinoma | Chemotherapy Effect | Immunotherapy | Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma | Molecular Targeted Therapy

China
Centre Hospitalier Universitaire de Nīmes

Completed

OTTAPE : Observatory on the Use of New Therapies (LED Photobiomodulation, Radiofrequency, Laser and Injectable Hyaluronic Acid) in the Treatment of Women's Pelvic-perineal Pathologies After Failure, Partial or Total, of First-line Medical Treatment (OTTAPE)

Pelvic-perineal Pathology

France
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy (PASSION)

Small-cell Lung Cancer

China
Henan Cancer Hospital

Completed

Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule

Soft Tissue Sarcomas

China
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment

Esophageal Squamous Cell Carcinoma

China
Shandong Cancer Hospital and Institute

Unknown

A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment

Non-Small-Cell Lung Cancer
Daiichi Sankyo, Inc.

Terminated

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Anaplastic Thyroid Cancer

United States
Celgene

Completed

AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Small Cell Lung Cancer

United States, United Kingdom, Australia, France, Canada, Netherlands, Poland, Spain, Switzerland, Italy, Denmark, Hungary, Germany, Bulgaria, Czechia, Austria, Belgium
Kirby Institute
Merck Sharp & Dohme LLC; amfAR, The Foundation for AIDS Research; Abbott

Completed

A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (SECOND-LINE)

HIV Infections

Taiwan, Australia, Argentina, Singapore, India, France, South Africa, Chile, Germany, Hong Kong, Ireland, Malaysia, Mexico, New Zealand, Nigeria, Peru, United Kingdom
Guangzhou Institute of Respiratory Disease
GeneCast Biotechnology Co., Ltd.

Unknown

Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform

Lung Cancer Non-small Cell Stage IV

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.

Osteosarcoma, Advanced

China
The First Affiliated Hospital of Zhengzhou University

Unknown

A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure

Hepatocellular Carcinoma
Sun Yat-sen University

Unknown

A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure

Non-Small Cell Lung Cancer

China
Hoffmann-La Roche

Completed

An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy (TIME)

Non-Squamous Non-Small Cell Lung Cancer

Belgium
Bristol-Myers Squibb

Completed

A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

HIV Infections

United States, Puerto Rico
Gruppo Oncologico Italiano di Ricerca Clinica

Recruiting

AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA (DURVASCC)

Extrapulmonary Small Cell Carcinoma

Italy
Zhou Chengzhi
Guangdong Provincial Hospital of Traditional Chinese Medicine; Sun Yat-sen... and other collaborators

Not yet recruiting

Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer

Small Cell Lung Cancer
Oregon Health and Science University
University of Washington; Bay Area First Step

Recruiting

Rural Community Peer Partnerships for Improving Methamphetamine-Associated Heart Failure Screening and Engagement (PEER-Heart)

Heart Failure | Methamphetamine Use

United States
Lee's Pharmaceutical Limited

Not yet recruiting

Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer
Ningbo No. 1 Hospital

Recruiting

First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)

Primary Central Nervous System Lymphoma

China
Jin-hong Chen

Not yet recruiting

Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM

CRC

China
Peking Union Medical College Hospital

Recruiting

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Marginal Zone Lymphoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer | Decitabine | Adebrelimab (SHR-1316)

China
Fudan University

Recruiting

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Advanced Breast Cancer | HR+/HER2- Breast Cancer

China
Bristol-Myers Squibb

Not yet recruiting

Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

Non-small Cell Lung Cancer (NSCLC)

United Kingdom
Sun Yat-sen University

Not yet recruiting

FOLFOX Chemotherapy Plus Fruquintinib and Sintilimab After First-line Treatment in Unresectable Hepatocellular Carcinoma (FOLFOX)

Hepatocellular Carcinoma | Immunotherapy | Second-line Treatment | Anti-angiogenic Therapy | FOLFOX Systemic Chemotherapy

3

Subscribe